Does starting a GLP-1 like Ozempic or Zepbound make you move less?

The research is more modest than the headlines suggest. A 2026 systematic review and meta-analysis pooling 7 studies and 924 patients found no statistically significant overall drop in objectively measured physical activity among people on a GLP-1, though it did find a slight reduction in free-living activity compared with control participants. If you feel like you are moving less, that is a real, documented pattern for some people, just not a universal or dramatic one.

Why would a GLP-1 lower how much someone moves, if the drug doesn't directly affect muscles?

The most likely explanation is indirect. As weight and inflammation-related joint or muscle discomfort improve for some people, activity can go either way, and low energy from reduced food intake, GI side effects, or feeling different in your body can quietly lower the amount of incidental movement in a day, the walking, stair-taking, and fidgeting that adds up. This is a behavior pattern worth watching, not a drug side effect with a mechanism the same way nausea is.

Does losing muscle on a GLP-1 make it harder to exercise?

Research on body composition changes during GLP-1 treatment consistently finds that most of the weight lost is fat, not muscle, which is reassuring for exercise capacity. That does not mean movement is unnecessary. Protecting the muscle you have with protein and resistance training, and staying active, is still what keeps your metabolism and physical function strong through the process.

What is a realistic way to stay active on a GLP-1 if motivation feels different?

Lower the bar instead of forcing a workout you do not have energy for. A 10-minute walk after a meal counts. Taking the stairs once a day counts. The goal on a GLP-1 is consistency at a smaller size, not matching the intensity you had before the medication. Build back up as energy returns, and talk to your doctor if fatigue is severe enough to affect basic daily activity.

Back to Blog

Does Exercise Really Decrease on a GLP-1? What the Research Shows, and How to Build Activity Back In

GLP-1 medications change appetite, not motivation to move, but the research shows a modest activity dip for some people. Here is what the evidence actually says and a low-bar way to rebuild movement.

Heather Bauer, RD · September 5, 2026

Here is the direct answer: for most people, a GLP-1 does not cause a dramatic activity crash, but the best current research does show a real, modest dip in day-to-day movement for some people, separate from anything happening with appetite. If you have noticed yourself walking less or skipping workouts since starting one, you are not imagining it, and you are not alone.

What does the research actually say about activity on a GLP-1?

Less than the online narrative around these drugs implies, and that is worth saying plainly. A 2026 systematic review and exploratory meta-analysis pooled 7 studies across 6 clinical trials, covering 924 patients, specifically to test whether GLP-1 receptor agonist treatment changes objectively measured physical activity, using devices like accelerometers and step counters rather than self-report (Kim, Chae & Moon, International Journal of Obesity, 2026). The finding: no statistically significant overall reduction in objectively measured physical activity, though patients on a GLP-1 did show a slight reduction in free-living activity compared with control participants. Real, but modest, is the honest read, not a wholesale activity collapse.

If muscle isn’t wasting away, why would movement drop at all?

The mechanism is more likely behavioral than physiological. Research on GLP-1 body composition changes consistently finds that most of the weight lost is fat, not lean tissue, which argues against “the drug is eating your muscle” as the explanation for less movement. A more likely story: appetite suppression means less food and less immediately available energy for some people, GI side effects like nausea can make anyone want to sit still, and joint or muscle discomfort tends to improve as weight comes down, which can cut either way depending on the person. None of that requires the muscle itself to be weaker. It just means the quiet, incidental movement that fills most people’s days, taking the stairs, parking farther away, pacing on a call, is an easy thing to lose without noticing.

Does this mean you should worry about losing muscle if you also move less?

Not on its own. The body-composition evidence on GLP-1s is reassuring here: weight lost on these medications is driven mainly by fat loss, with lean tissue relatively better preserved than the drug’s reputation suggests (Sawicka-Gutaj, Gruszczyński et al., International Journal of Obesity, 2026). That is not permission to skip movement and protein, though. It is the difference between “muscle loss is inevitable on this drug” (not accurate) and “muscle loss is preventable with the same basics that protect it for anyone losing weight” (accurate, and worth doing anyway). The protein target that protects muscle on a GLP-1 is the other half of this picture.

How do you actually build activity back in when motivation feels different?

Lower the bar instead of forcing your old routine. A 10-minute walk after a meal counts. One flight of stairs instead of the elevator counts. If a full workout feels like too much most days, three short walks do more for a suppressed-appetite, lower-energy week than one workout you keep skipping out of guilt. The goal is not matching your pre-medication intensity. It is staying consistent at whatever size effort actually fits the week you are having, and building back up as energy returns.

If fatigue is severe enough that basic daily activity feels hard, that is worth a conversation with your prescriber rather than something to push through on willpower. A GLP-1 changing your appetite and energy is expected. A GLP-1 making you unable to function day to day is not, and deserves a doctor’s eyes, not a pep talk.

The bottom line

The research shows a real but modest dip in activity for some people on a GLP-1, not the dramatic crash the headlines sometimes suggest, and it is not driven by muscle wasting. Lower the bar on what counts as movement, protect protein and strength work regardless, and loop in your doctor if fatigue crosses from “different” into “can’t function.” Daily coaching built around exactly this phase of GLP-1 treatment is what keeps activity and nutrition working together instead of one quietly slipping while you focus on the other.